Business Context and Reporting Period
Chemomab Therapeutics Ltd. filed a Form 6-K on August 22, 2025, for the month of August 2025. The filing announces a corporate action regarding its American Depositary Shares (ADSs) rather than reporting operational or financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notice of a capital structure adjustment and contains no financial statements.
Material Changes
The primary material change is a ratio adjustment of ADSs to ordinary shares, effective August 26, 2025:
- Current Ratio: 1 ADS represents 20 ordinary shares.
- New Ratio: 1 ADS represents 80 ordinary shares.
- Impact: This functions as a one-for-four reverse ADS split.
- Execution: The depositary bank (Bank of New York Mellon) will exchange every four existing ADSs for one new ADS automatically.
- Fractional Shares: Aggregated and sold by the depositary bank, with net proceeds distributed to holders.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the mechanics of the split. The company will continue to trade on the Nasdaq Capital Market under the ticker "CMMB" with an updated CUSIP Number of 16385C203.
Investor Verification Checklist
- Confirm the effective date of the ratio change is August 26, 2025.
- Verify the new CUSIP Number (16385C203) for trading purposes.
- Understand that no action is required from ADS holders for the exchange.
- Note that fractional shares will be liquidated by the depositary bank rather than issued.